These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16341288)

  • 1. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exenatide.
    Barnett A
    Expert Opin Pharmacother; 2007 Oct; 8(15):2593-608. PubMed ID: 17931093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
    Iltz JL; Baker DE; Setter SM; Keith Campbell R
    Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
    Schnabel CA; Wintle M; Kolterman O
    Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
    Parkes DG; Mace KF; Trautmann ME
    Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M; Bajaj M
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N
    South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of exenatide as a diabetes therapeutic.
    Bhavsar S; Mudaliar S; Cherrington A
    Curr Diabetes Rev; 2013 Mar; 9(2):161-93. PubMed ID: 23256660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide can reduce glucose independent of islet hormones or gastric emptying.
    Ionut V; Zheng D; Stefanovski D; Bergman RN
    Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E269-77. PubMed ID: 18492781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glucagon-like peptide 1 (GLP-1)].
    Parhofer KG
    MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C; Beruto V; Keller G; Santoro S; Di Girolamo G
    Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.